Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.

Credit: Thinkstock. The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS. The Food and Drug Administration (FDA) has approved Tecentriq ...

Tecentriq was approved by the FDA for adults and children aged two years and older with advanced alveolar soft part sarcoma, a disease typically diagnosed in approximately 80 patients per year in the ...

The positions in the table below reflect the Cure Alveolar Soft Part Sarcoma International's position overall, domestically, within their sector, and in various subject areas based on their Share.

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis. This is an ASCO ...

Using Recentin (cediranib) can help stabilize disease in patients with alveolar soft-part sarcoma, a rare sarcoma subset. The use of Recentin (cediranib) can play an important role in long-term ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic ...